Chronic inflammatory demyelinating CIDP

PARK p-adrenergic receptor kinase CIDP chronic inflammatory demyelinating polyneuropathy... 

FIGURE 20.61 Locations of T lymphocytes among sural nerve biopsy specimens from 13 cases of chronic inflammatory demyelinat-ing polyneuropathy (CIDP) and 22 cases of Guillain-Barre syndrome (CBS). Percentages positive are as reported in Schmidt B, Toyka KV, Keifer R, et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve. 1996 19 474-487. 

Observational studies In an observational study in 51 patients with primary immunodeficiencies with 642 infusions, drug-related adverse reactions occurred during six infusions in four patients none was serious [51 ]. In another study in 46 patients with primary immunodeficiency, 20% of the 601 infusions were associated with treatment-related adverse events, none of which was serious. Of the treatment-related adverse events, 59% were categorized as mild, 36% as moderate, and 5% as severe most were transient [44. In a safety study in 208 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 113 patients were exposed to 1096 infusions of intravenous immunoglobulin 55% had drug-related adverse events, an adverse event rate of 18 per 100 infusions, with five serious adverse reactions during the 1-year study [45. ... 

In a patient who does have a close family history of diabetes-2, a glucocorticoid should be avoided if possible, because it can increase insulin resistance and make manifest diabetes-2 glucose dysmetabo-lism. Accordingly, asking about a close family history of diabetes-2 is very important in managing a chronic immune dysschwannian polyneuropathy (CIDP) (sometimes less precisely called chronic inflammatory demyelinating polyneuropathy), or other dysimmune patient. 

Treatment Because of the sensory abnormalities, dysschwannian nerve conductions, elevated CSF protein, aspects of denervation-reinnervation in the muscle biopsy, and the diabetes-2 in both parents, we considered that our patient probably had coexisting genetico-diahetoid-2 dysimmune neuropathy," a type of chronic immune dysschwannian polyneuropathy (CIDP) (sometimes less precisely called chronic inflammatory demyelinating polyneuropathy, Chapter 2). We therefore treated her using/WG, and she was remarkably benefited her walking ability and endurance greatly improved, she did not require frequent rests, and was able to ascend steps much more easily. 

---